Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

This study is currently recruiting participants.
Verified October 2013 by Dana-Farber Cancer Institute
Sponsor:
Collaborators:
Novartis
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Irene Ghobrial, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01125293
First received: March 16, 2010
Last updated: October 16, 2013
Last verified: October 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2015
  Estimated Primary Completion Date: October 2014 (Final data collection date for primary outcome measure)